Every drug approved for Parkinson’s disease does the same thing: it manages symptoms. None slows the underlying destruction ...

Key proteins implicated in neurodegenerative diseases are alpha synuclein and tau. Tau aggregation into neurofibrillary tangles, along with amyloid-beta aggregation into plaques, is a hallmark of ...

Studies have uncovered that abnormalities in the alpha-synuclein protein are likely a causal factor for numerous diseases, including Parkinson’s disease, multiple system atrophy (MSA), dementia with ...

For decades, Parkinson’s disease research focused almost exclusively on protein misfolding, but 2025-2026 lipidomics breakthroughs have upended this view by demonstrating that lipid droplets actively ...

Amsterdam, NL, November 13, 2019 - Aggregates of the protein alpha-synuclein arising in the gut may play a key role in the development of Parkinson's disease (PD). Investigators are testing the ...

In 2020, Ashley Harms, Ph.D., and University of Alabama at Birmingham colleagues published an Acta Neuropathologica study that used a mouse model to show that the alpha-synuclein pathology from ...

Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by the aggregation of alpha-synuclein in the brain. Now, scientists have developed a radioligand that facilitates the ...

Scientists have carried out an extensive study of a newly discovered mutation that can uncover new insights into the molecular basis of pathology formation in a family of disorders that includes Lewy ...

Skin biopsies detected phosphorylated alpha-synuclein in a high proportion of people with Parkinson's disease and other synucleinopathies. Finding a reliable diagnostic biomarker for synucleinopathies ...

A new study, published in the journal eNeuro, suggests the answer is no. If this is borne out, that result differs from Alzheimer’s disease, where reducing endogenous tau levels in brain neurons is ...